<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05126836</url>
  </required_header>
  <id_info>
    <org_study_id>STUDY00011678</org_study_id>
    <nct_id>NCT05126836</nct_id>
  </id_info>
  <brief_title>Cilostazol for HFpEF</brief_title>
  <official_title>Cilostazol for HFpEF (Heart Failure With a Preserved Ejection Fraction)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Minnesota</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Minnesota</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Determine if cilostazol improves symptoms and NTproBNP levels (heart failure blood marker) in&#xD;
      heart failure with preserved ejection fraction (HFpEF) - a prevalent syndrome without&#xD;
      targeted evidence-based treatment.&#xD;
&#xD;
      This will be assessed in a prospective 1-month single blinded study with 2 cross-overs n-of-1&#xD;
      study design with placebo and cilostazol&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Heart failure (HF) is the #1 reason for hospital admissions. About half of the patients with&#xD;
      HF have a preserved ejection fraction (HFpEF). There is no targeted evidence-based treatment&#xD;
      for HFpEF. We recently reported that elevating the heart rate with pacemakers conveys&#xD;
      clinical benefits e.g. reduction in heart failure symptoms, lowering filling pressures and an&#xD;
      increase in walk distance. Cilostazol is a PDE3 inhibitor that increases the heart rate by&#xD;
      about 5-8 beats per minute and has other potentially beneficial HFpEF effects such as&#xD;
      peripheral vasodilation, lusitropic effects and dromotropic effects. By activating&#xD;
      proteinkinase A, cilostazol may also phosphorylate titin, which may reduce myocardial&#xD;
      stiffness.&#xD;
&#xD;
      n-of-1 study design using the standard dose cilostazol formulation of 100mg twice a day&#xD;
      approved for peripheral vascular disease. The investigators and patients are blinded. The&#xD;
      patients serve as their own controls with two crossovers (Week 1: cilostazol or placebo -&#xD;
      Week 2: placebo or cilostazol - Week 3: cilostazol or placebo - Week 4: placebo or&#xD;
      cilostazol).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2021</start_date>
  <completion_date type="Anticipated">July 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>n-of-1 design</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>KCCQ-12</measure>
    <time_frame>4 weeks</time_frame>
    <description>The Kansas City Cardiomyopathy Questionnaire contains 12 items that measure the effect of heart failure on health and quality of life. Total scores are scaled from 0 to 100 and frequently summarized in 25-point ranges, where scores represent health status as follows: 0 to 24: very poor to poor; 25 to 49: poor to fair; 50 to 74: fair to good; and 75 to 100: good to excellent</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>NTproBNP</measure>
    <time_frame>1st week and 3rd week</time_frame>
    <description>Blood marker of heart failure severity [pg/mL]</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Heart Failure With Preserved Ejection Fraction</condition>
  <arm_group>
    <arm_group_label>Cilostazol first, then Placebo</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>First week, Cilostazol 100mg twice a day&#xD;
Second week, Placebo twice a day&#xD;
Third week, Cilostazol 100mg twice a day&#xD;
Forth week, Placebo twice a day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo first, then Cilostazol</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>First week, Placebo twice a day&#xD;
Second week, Cilostazol 100mg twice a day&#xD;
Third week, Placebo twice a day&#xD;
Forth week, Cilostazol 100mg twice a day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cilostazol 100Mg Tab</intervention_name>
    <description>Cilostazol Twice a Day</description>
    <arm_group_label>Cilostazol first, then Placebo</arm_group_label>
    <arm_group_label>Placebo first, then Cilostazol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Cilostazol first, then Placebo</arm_group_label>
    <arm_group_label>Placebo first, then Cilostazol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  &gt;18 yrs&#xD;
&#xD;
          -  LVEF ≥ 50% (on last assessment, &lt;2 years)&#xD;
&#xD;
          -  Diagnosis of HFpEF or Shortness of breath with NYHA Class ≥ 2 and one of the&#xD;
             following:&#xD;
&#xD;
               1. pulmonary edema on chest imaging or documented on exam or on loop diuretics&#xD;
&#xD;
               2. NTproBNP &gt;400 ng/ml in the last 24 months&#xD;
&#xD;
               3. HFpEF&gt;50% hospitalization in the last 3 years&#xD;
&#xD;
               4. Qualitative echo: &gt; mild diastolic dysfunction on echo report and &gt; mild left&#xD;
                  ventricular hypertrophy and left atrial dilation or quantitative echo: left&#xD;
                  ventricular hypertrophy [men ≥115 g/m², women ≥95 g/m² or relative wall thickness&#xD;
                  &gt;0.42 or any LV wall thickness &gt;1.2cm and has LA dilation (&gt;28ml/m2)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  &lt;18yo&#xD;
&#xD;
          -  resting heart rate &gt;100/min&#xD;
&#xD;
          -  patients with LVEF &lt;50%&#xD;
&#xD;
          -  advanced end-stage heart failure,&#xD;
&#xD;
          -  symptomatic COPD on home O2,&#xD;
&#xD;
          -  uncontrolled severe HTN (SBP &gt;160/100 mmHg)&#xD;
&#xD;
          -  patients with life expectancy &lt;6 months,&#xD;
&#xD;
          -  end-stage liver cirrhosis,&#xD;
&#xD;
          -  more than moderate valve disease,&#xD;
&#xD;
          -  infiltrative myocardial disease&#xD;
&#xD;
          -  constrictive pericarditis or myocarditis,&#xD;
&#xD;
          -  patients unable to participate in follow up,&#xD;
&#xD;
          -  pregnant patients or patients without reliable contraceptive agent for the duration of&#xD;
             study participation),&#xD;
&#xD;
          -  left ventricular outflow tract obstruction,&#xD;
&#xD;
          -  bleeding dyscrasias, blood dyscrasias,&#xD;
&#xD;
          -  Patients on oral ketoconazole, itraconazole, fluconazole, miconazole, fluvoxamine,&#xD;
             fluoxetine, nefazodone, sertraline, erythromycin, clarithromycin or azithromycin&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Markus Meyer, MD</last_name>
    <phone>612-625-9538</phone>
    <email>meye3249@umn.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Alexi Tamas, MD</last_name>
    <phone>612-367-7883</phone>
    <email>alexy001@umn.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>M Health Fairview</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emily Walser</last_name>
      <phone>612-626-3656</phone>
      <email>emilyw@umn.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 1, 2021</study_first_submitted>
  <study_first_submitted_qc>November 18, 2021</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 19, 2021</study_first_posted>
  <last_update_submitted>November 18, 2021</last_update_submitted>
  <last_update_submitted_qc>November 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cilostazol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

